Jorg Rademaker

Medis Medical Imaging, the leading cardiac imaging software company, announces today the FDA clearance of the latest version of its groundbreaking Medis QFR® in the USA

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), and Medis Medical Imaging, a leading cardiac imaging software company, announced today that they have entered into a strategic partnership, in the United States, to enhance cardiovascular care through the utilization of both ePRISM – Terumo’s proprietary clinical decision support platform – and Medis’ Quantitative Flow Ratio (QFR) technology, a non-invasive software solution designed to assess angiography-derived coronary physiology.

Medis’ Quantitative Flow Ratio (QFR®) has been awarded with a Class I recommendation in 3 distinct categories of the 2024 ESC guidelines for the management of patients suffering from chronic coronary syndrome (CCS). This recognition recommends QFR® as a physiology measurement technique next to, and at par with, the traditional wire-based methods. The guidelines also differentiate Medis QFR® from other Angiography-based FFR techniques, which have been called out with a lower IIb/C recommendation, in only one of the 3 categories.